All In Biotech

Drug Trial Radar · NCT01508936

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma

Last checked: Nov 20, 2026Latest source record: Jun 27, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 511 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

511

Actual

Start

Feb 2012

Primary completion

Aug 2013

Study completion Aug 2013

Sponsor

Sponsor type
Industry
First posted
Jan 12, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to characterize the efficacy of reslizumab treatment, at a dosage of 3.0 milligrams per kilogram (mg/kg) every 4 weeks for a total of 4 doses, in improving pulmonary function in relation to baseline blood eosinophil levels in patients with moderate to severe asthma, as assessed by the change from baseline to week 16 in forced expiratory volume in 1 second (FEV1).

Conditions

  • Eosinophilic Asthma

Interventions

  • ReslizumabDrug

    Reslizumab administered at a dosage of 3.0 mg/kg by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).

  • PlaceboDrug

    Matching placebo administered by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in Full Analysis SetTime frame: Baseline (Day 1), Week 16

Locations

66 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site 861

    Birmingham, Alabama

  • Investigational Site 842

    Homewood, Alabama

  • Investigational Site 887

    Jasper, Alabama

  • Investigational Site 809

    Tucson, Arizona

  • Investigational Site 892

    Tucson, Arizona

  • Investigational Site 846

    Little Rock, Arkansas

  • Investigational Site 828

    Anaheim, California

  • Investigational Site 900

    Fresno, California

  • Investigational Site 862

    Huntington Beach, California

  • Investigational Site 852

    Los Angeles, California

  • Investigational Site 909

    Los Angeles, California

  • Investigational Site 864

    Newport Beach, California

  • Investigational Site 812

    Rancho Mirage, California

  • Investigational Site 808

    Riverside, California

  • Investigational Site 804

    Sacramento, California

  • Investigational Site 837

    Centennial, Colorado

  • Investigational Site 851

    Denver, Colorado

  • Investigational Site 832

    Wheat Ridge, Colorado

  • Investigational Site 855

    Jacksonville, Florida

  • Investigational Site 865

    Miami, Florida

  • Investigational Site 881

    Miami, Florida

  • Investigational Site 805

    Albany, Georgia

  • Investigational Site 870

    Stockbridge, Georgia

  • Investigational Site 816

    Chicago, Illinois

  • Investigational Site 824

    Shiloh, Illinois

  • Investigational Site 883

    Evansville, Indiana

  • Investigational Site 878

    Fort Wayne, Indiana

  • Investigational Site 820

    Lenexa, Kansas

  • Investigational Site 873

    Owensboro, Kentucky

  • Investigational Site 801

    Lafayette, Louisiana

  • Investigational Site 877

    Mandeville, Louisiana

  • Investigational Site 875

    White Marsh, Maryland

  • Investigational Site 871

    Fall River, Massachusetts

  • Investigational Site 834

    North Dartmouth, Massachusetts

  • Investigational Site 889

    Troy, Michigan

  • Investigational Site 838

    Rolla, Missouri

  • Investigational Site 818

    St Louis, Missouri

  • Investigational Site 841

    St Louis, Missouri

  • Investigational Site 857

    Albuquerque, New Mexico

  • Investigational Site 819

    Newburgh, New York

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.